EASI-SWITCH

Trial Acronym	EASI-SWITCH
Clinical Area	Cancer
Trial Title	Interventional study comparing whether early switch to oral antibiotics 12-24 hours after intravenous antibiotic treatment commences in patients with low risk of neutropenic sepsis is non-inferior to standard care. This is a randomised, controlled, non-inferiority trial with allocation concealment. Both arms of the trial will be conducted in parallel.
Status	Analysis and Reporting
Trial Registration	https://www.isrctn.com/ISRCTN84288963

---

• Recruitment

  Recruitment Target	628
  Date Open to Recruitment	December 2015
  Recruitment	129
  Date Closed to Recruitment	November 2018

• Trial Design

  Trial Design	A multi-centre, interventional, randomised, controlled, non-inferiority trial with allocation concealment.
  Study Aim	To establish the clinical and cost-effectiveness of early switch to oral antibiotics, 12-24 hours after intravenous antibiotic treatment commences in low risk cancer patients with neutropenic sepsis.

• Chief Investigator

  Chief Investigator	Dr Victoria Coyle, Queen’s University Belfast v.coyle@qub.ac.uk Dr Ronan McMullan, Queen’s University Belfast

• Sponsor & Funder

   

  Sponsor	Belfast Health & Social Care Trust
  Funder	National Institute for Health and Care Research Health Technology Assessment https://fundingawards.nihr.ac.uk/award/13/140/05